How has been the historical performance of Kabra Drugs?

Answer:The historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, peaking at 0.02 Cr in March 2020 before declining to zero in subsequent years. The company's expenditures have increased significantly, with total expenditure rising from 0.14 Cr in March 2019 to 1.72 Cr in March 2025, primarily driven by escalating employee costs and other expenses. As a result, the operating profit has been negative, culminating in a loss of -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, with losses growing from -0.16 Cr in March 2019 to -1.09 Cr in March 2025. The company's equity capital has seen a substantial increase to 23.71 Cr in March 2025, up from 4.39 Cr in the previous years, while reserves have improved to 0.95 Cr from negative values in earlier years. Cash flow from financing activities has been positive, with a notable inflow of 23.00 Cr in March 2025, contributing to a closing cash balance of 21.00 Cr.

Breakdown:
Kabra Drugs has not generated any significant revenue over the years, with net sales consistently at zero from March 2021 to March 2025, except for a minor figure in March 2019. The total operating income peaked at 0.02 Cr in March 2020 but has since declined to zero. Expenditures have escalated, particularly in employee costs and other expenses, leading to increasing operating losses, which reached -1.08 Cr in March 2025. The company has also seen a rise in equity capital to 23.71 Cr, while reserves have turned positive at 0.95 Cr. Despite ongoing losses, cash flow from financing activities has provided a significant boost, resulting in a closing cash balance of 21.00 Cr as of March 2025.